Core Insights - Shandong Wohuah Pharmaceutical Technology Co., Ltd. is the first A-share listed company to disclose its 2025 annual report, showing a revenue of 817 million yuan, a year-on-year increase of 6.96%, and a net profit attributable to shareholders of 95.71 million yuan, a significant increase of 162.93% [2] Group 1: Financial Performance - In 2025, the company achieved a revenue of 817 million yuan, reflecting a growth of 6.96% year-on-year [2] - The net profit attributable to shareholders reached 95.71 million yuan, marking a substantial increase of 162.93% compared to the previous year [2] Group 2: Product Portfolio and Market Strategy - Wohuah Pharmaceutical has developed a product matrix covering over ten therapeutic areas, with 161 drug approval numbers and 15 exclusive products [2] - Key products such as Wohuah® Xinkeshu Tablets and Bone Health Capsules are central to the company's revenue and profit [2] - The company has established a qualification access system, with 91 products included in the national medical insurance directory and 43 in the national essential drug list, creating a multi-layered product barrier [2] Group 3: Marketing and Sales Channels - The company is expanding its marketing system to grassroots and outpatient markets, with its core product Wohuah® Xinkeshu Tablets newly entering 165 county-level medical community directories [2] - In 2025, revenue from the outpatient market reached approximately 103 million yuan, accounting for 12.6% of total revenue, with e-commerce sales growing by 113% year-on-year [3] Group 4: Operational Efficiency and Management - Wohuah Pharmaceutical is implementing a refined management strategy aimed at reducing costs while increasing sales, efficiency, and cash flow [3] - The company is also focusing on the intelligent upgrade of its production system and supply chain, optimizing capacity layout and inventory turnover efficiency [3] Group 5: Shareholder Returns and Future Outlook - The company plans to distribute a cash dividend of 1.46 yuan per 10 shares (including tax) to its shareholders [4] - Looking ahead, Wohuah Pharmaceutical aims to maintain strategic focus on traditional Chinese medicine and leverage its solid financial structure for potential capital operations [4]

Core Viewpoint - Wohuah Pharmaceutical has reported a significant turnaround in its financial performance for the year 2025, with notable increases in revenue and net profit compared to previous years [1][3]. Financial Performance - In 2025, Wohuah Pharmaceutical achieved an operating revenue of 816.95 million yuan, representing a year-on-year growth of 6.96% [2]. - The net profit attributable to shareholders reached 95.72 million yuan, marking a substantial increase of 162.93% from the previous year [2]. - Basic earnings per share were reported at 0.17 yuan, an increase of 183.33% compared to 0.06 yuan in 2024 [2]. Cash Flow and Assets - The net cash flow from operating activities was 128.53 million yuan, up 40.45% from 91.51 million yuan in 2024 [2]. - Total assets at the end of 2025 were 977.37 million yuan, a slight decrease of 0.85% from 985.73 million yuan in 2024 [2]. - The net assets attributable to shareholders increased by 3.79% to 723.82 million yuan compared to 697.37 million yuan in 2024 [2]. Product Performance - The cardiovascular system drugs generated revenue of 56.90 million yuan, a growth of 12.31% [2]. - Revenue from musculoskeletal system drugs decreased by 2.03% to 18.30 million yuan [2]. - Antiviral respiratory system drugs saw an increase in revenue to 26.09 million yuan, up 18.46% [2]. Dividend Distribution - The company plans to distribute a cash dividend of 1.46 yuan per 10 shares, totaling 84.27 million yuan, based on a total share capital of 577 million shares as of December 31, 2025 [3]. Market Reaction - On January 19, the stock price of Wohuah Pharmaceutical rose by 2.27%, closing at 7.66 yuan per share, with an intraday high of 7.78 yuan, the highest since January 2022 [4].

Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has become the first listed company in the A-share market to release its 2025 annual report, indicating the start of the annual performance reporting period for the market. This reflects the company's strong governance, internal control quality, and commitment to transparent information disclosure, showcasing management's confidence in operational quality and financial health [2] Financial Performance - In 2025, Wohuah Pharmaceutical achieved total operating revenue of 817 million yuan, a steady increase of 6.96% year-on-year. The net profit attributable to shareholders reached 95.7153 million yuan, a significant increase of 162.93%, marking the highest growth rate in nearly a decade. Notably, the net profit growth rate significantly outpaced revenue growth, indicating a structural improvement in profitability and quality of growth [2][3] Strategic Initiatives - The company has consistently adhered to a strategy of maintaining a strong exclusive product line. In response to deepening industry policies and increasing market competition, Wohuah Pharmaceutical has built competitive barriers through its exclusive products, including Wohuah® Xinkeshu tablets and other key products, enhancing market competitiveness [3] - The net profit growth exceeding revenue growth is attributed to the premium capability of high-value product combinations and refined cost control, demonstrating the resilience of the product line across policy cycles [3] Cash Flow and Financial Health - During the reporting period, the net cash flow from operating activities increased by 40.45%, and the asset-liability structure remained highly stable with zero interest-bearing debt. This reflects the company's excellent financial health and strong internal cash generation capability, providing a solid foundation for sustainable operations and strategic initiatives [3] Dividend Policy - The board of directors approved a cash dividend plan, proposing a distribution of 1.46 yuan (tax included) for every 10 shares. This move demonstrates management's confidence in the company's future profitability and cash position, as well as a commitment to shareholder returns under a "zero interest-bearing debt" operational model [4] Future Outlook - Looking ahead to 2026, Wohuah Pharmaceutical plans to deepen its focus on traditional Chinese medicine, emphasizing the clinical value and market synergy of its exclusive product line. The company aims to respond prudently to ongoing procurement policies and actively expand its outpatient market while enhancing research and access strategies [4]

Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has reported a significant increase in net profit for 2025, achieving a 162.93% year-on-year growth, marking the highest increase in nearly a decade, despite a challenging industry environment [2] Group 1: Financial Performance - In 2025, Wohuah Pharmaceutical achieved total revenue of 817 million yuan, representing a year-on-year growth of 6.96% [2] - The net profit attributable to shareholders reached 95.72 million yuan, reflecting a substantial increase of 162.93% [2] - The net cash flow from operating activities increased by 40.45% year-on-year, indicating strong cash generation capabilities [2] Group 2: Strategic Initiatives - The company has maintained a "strong exclusive product line" strategy, focusing on proprietary products in the cardiovascular and chronic disease sectors [2] - Wohuah Pharmaceutical plans to implement a strategic optimization and restructuring of its production system in 2025, aiming for efficient integration and cost reduction [3] - The company intends to deepen its focus on proprietary product lines and enhance clinical value and market synergy while responding to ongoing procurement policies [3] Group 3: Future Outlook - Wohuah Pharmaceutical aims to strengthen its research and access strategies, leveraging a solid financial structure for potential capital operations around its core business [3] - The company is expected to continue benefiting from favorable policies supporting the traditional Chinese medicine market, which is projected to maintain rapid growth [3]

沃华医药（002107）(002107.SZ)发布2025年年度报告，该公司营业收入为8.17亿元，同比增长6.96%。 归属于上市公司股东的净利润为9571.53万元，同比增长162.93%。归属于上市公司股东的扣除非经常性 损益的净利润为9210.67万元，同比增长168.20%。基本每股收益为0.17元。此外，拟向全体股东每10股 派发现金红利1.46元(含税)。 ...

Core Viewpoint - Wohua Pharmaceutical (002107.SZ) reported a revenue of 817 million yuan for the year 2025, reflecting a year-on-year growth of 6.96% [1] - The net profit attributable to shareholders reached 95.71 million yuan, marking a significant increase of 162.93% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 92.11 million yuan, up by 168.20% year-on-year [1] - The basic earnings per share stood at 0.17 yuan [1] - The company proposed a cash dividend of 1.46 yuan (including tax) for every 10 shares to all shareholders [1]

新京报贝壳财经讯 1月19日，沃华医药公告，公司2025年度合并报表归属于上市公司股东的净利润 9571.53万元，母公司可供股东分配利润为9125.95万元。公司可供股东分配利润为8466.1万元。公司拟 以2025年12月31日的总股本5.77亿股为基数，向全体股东每10股派发现金红利人民币1.46元(含税)，共 计派发现金红利8427.26万元(含税)，不送红股，不以公积金转增股本。本利润分配预案实施后，公司 2025年度累计现金分红总额为1.54亿元，占本年度归属于上市公司股东的净利润160.41%。 ...

沃华医药公告，公司2025年度合并报表归属于上市公司股东的净利润9571.53万元，母公司可供股东分 配利润为9125.95万元。公司可供股东分配利润为8466.1万元。公司拟以2025年12月31日的总股本5.77亿 股为基数，向全体股东每10股派发现金红利人民币1.46元（含税），共计派发现金红利8427.26万元（含 税），不送红股，不以公积金转增股本。本利润分配预案实施后，公司2025年度累计现金分红总额为 1.54亿元，占本年度归属于上市公司股东的净利润160.41%。 ...

格隆汇1月19日丨沃华医药(002107.SZ)公布2025年年度报告，报告期内，公司实现营业收入81,695.24万 元，同比增长6.96%；实现归属于上市公司股东的净利润9,571.53万元，同比增长162.93%。主要产品线 中，心脑血管系统药品营业收入56,880.65万元,同比增长12.31%；肌肉骨骼系统药品营业收入18,250.42 万元，同比下降2.03%；抗病毒类呼吸系统药品营业收入2,609.23万元，同比增长18.46%。向全体股东 每10股派发现金红利1.46元。 ...

Core Insights - Shandong Wohua Pharmaceutical reported a revenue of 817 million yuan for the fiscal year 2025, marking a year-on-year increase of 6.96% [1] - The net profit attributable to shareholders reached 95.71 million yuan, a significant increase of 162.93%, the highest growth rate in nearly a decade [1] Financial Performance - The company's operating cash flow increased by 25% year-on-year, indicating strong cash generation capabilities [2] - The asset-liability structure remains robust, with zero interest-bearing debt [1] Strategic Initiatives - Wohua Pharmaceutical plans to implement a cash dividend scheme of 1.46 yuan per 10 shares, building on a previous dividend of 1.20 yuan [2] - The company announced a strategic optimization and restructuring of its production system to achieve cost reduction through resource synergy and intelligent upgrades [2] Future Outlook - For 2026, the company aims to deepen its focus on traditional Chinese medicine, respond effectively to ongoing procurement policies, and expand its outpatient market [2] - Wohua Pharmaceutical will enhance its research and access strategies, aiming for operational efficiency through meticulous management practices [2]